Hatch-Waxman Integrity Act of 2018

Bill Number

HR 7251

Introduced

Dec 11, 2018

Latest Action

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period t ...

Sponsor

Cosponsors

Topics

Administrative remedies Drug safety, medical device, and laboratory regulation Fraud offenses and financial crimes Health Intellectual property Licensing and registrations Prescription drugs Securities

Full Text

View Full Bill Text

Votes

Summary

Hatch-Waxman Integrity Act of 2018

This bill amends the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent a generic drug or biosimilar manufacturer from using a specific review process for challenging pharmaceutical drug or biologic patents.

Actions

Dec 11, 2018

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Dec 11, 2018

Introduced in House

Amendments

Related Bills